Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Common Equity (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Common Equity over the past 3 years, most recently at $245.2 million for Q4 2025.

  • Quarterly results put Common Equity at $245.2 million for Q4 2025, up 75.66% from a year ago — trailing twelve months through Dec 2025 was $245.2 million (up 75.66% YoY), and the annual figure for FY2025 was $245.2 million, up 75.66%.
  • Common Equity for Q4 2025 was $245.2 million at Tonix Pharmaceuticals Holding, up from $231.1 million in the prior quarter.
  • Over the last five years, Common Equity for TNXP hit a ceiling of $245.2 million in Q4 2025 and a floor of $42.1 million in Q2 2024.
  • Median Common Equity over the past 3 years was $140.0 million (2023), compared with a mean of $143.4 million.
  • Biggest five-year swings in Common Equity: tumbled 70.03% in 2024 and later skyrocketed 299.02% in 2025.
  • Tonix Pharmaceuticals Holding's Common Equity stood at $105.5 million in 2023, then skyrocketed by 32.25% to $139.6 million in 2024, then surged by 75.66% to $245.2 million in 2025.
  • The last three reported values for Common Equity were $245.2 million (Q4 2025), $231.1 million (Q3 2025), and $168.0 million (Q2 2025) per Business Quant data.